Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: J Pharmacokinet Pharmacodyn. 2015 Sep 15;42(5):553–571. doi: 10.1007/s10928-015-9447-8

Figure 3. Systems PK models developed for ADCs.

Figure 3

(A) A tumor disposition model developed to characterize and predict the concentrations of ADC and its components in the plasma and solid tumor [44]. (B) A PBPK model developed to characterize and predict the concentrations of ADC and its components throughout the body [45].